HUM250117C340000
- 0.05
- -0.10-66.67%
Humana Newsroom
Piper Sandler Maintains Humana(HUM.US) With Hold Rating, Raises Target Price to $288
Truist Financial Maintains Humana(HUM.US) With Hold Rating, Announces Target Price $290
Humana Analyst Ratings
Baird Maintains Humana(HUM.US) With Hold Rating, Cuts Target Price to $270
Baird Adjusts Humana Price Target to $270 From $374, Maintains Neutral Rating
Morgan Stanley raises the Target Price for Humana to $301.
Humana Is Maintained at Equal-Weight by Morgan Stanley
Humana Analyst Ratings
Morgan Stanley Maintains Humana(HUM.US) With Hold Rating, Raises Target Price to $301
Morgan Stanley Sticks to Their Hold Rating for Humana (HUM)
Piper Sandler Maintains Humana(HUM.US) With Hold Rating, Cuts Target Price to $270
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Alcon (ALC) and Humana (HUM)
Nephron Initiates Humana(HUM.US) With Hold Rating, Announces Target Price $294
Nephron Research Downgrades Humana to Hold From Buy, $294 Price Target
Stephen Baxter's Buy Rating Driven by Strategic CFO Appointment and Positive EPS Outlook for Humana
Cautious Hold Rating on Humana Amid Transition and Uncertainty
Wells Fargo Maintains Humana(HUM.US) With Buy Rating, Raises Target Price to $315
Wells Fargo Adjusts Price Target on Humana to $315 From $290, Maintains Overweight Rating
Humana (HUM) Receives a Buy From Wells Fargo
JPMorgan Adjusts Price Target on Humana to $257 From $254, Keeps Neutral Rating